Edwin L. Madison

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA.

Torrey Pines Institute for Molecular Studies, Inc. operates as a non-profit research center. The firm conducts research in various fields including: multiple sclerosis, cancer, heart disease, types I and II diabetes, macular degeneration, pain management, alzheimer's disease, inflammatory disorders, AIDS and other infectious diseases, regenerative medicine, obesity, transplant rejection, muscle wasting syndrome, rheumatoid arthritis and new methods for drug discovery. The company was founded by Dr. Richard A. Houghten in 1988 and is headquartered in Port St. Lucie, FL.

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.